Debruyne FM - Search Results

1

Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors.

Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Bringuier PP, et al. Among authors: debruyne fm. Cancer Res. 1993 Jul 15;53(14):3241-5. Cancer Res. 1993. PMID: 8324734

2

Expression of markers for transitional cell carcinoma in normal bladder mucosa of patients with bladder cancer.

Witjes JA, Umbas R, Debruyne FM, Schalken JA. Witjes JA, et al. Among authors: debruyne fm. J Urol. 1995 Dec;154(6):2185-9. J Urol. 1995. PMID: 7500486

3

Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.

Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA. Umbas R, et al. Among authors: debruyne fm. Cancer Res. 1994 Jul 15;54(14):3929-33. Cancer Res. 1994. PMID: 7518346

4

Molecular prognostic factors in bladder cancer.

Vet JA, Debruyne FM, Schalken JA. Vet JA, et al. Among authors: debruyne fm. World J Urol. 1994;12(2):84-8. doi: 10.1007/BF00184242. World J Urol. 1994. PMID: 7916239 Review.

5

p53 mutations have no additional prognostic value over stage in bladder cancer.

Vet JA, Bringuier PP, Poddighe PJ, Karthaus HF, Debruyne FM, Schalken JA. Vet JA, et al. Among authors: debruyne fm. Br J Cancer. 1994 Sep;70(3):496-500. doi: 10.1038/bjc.1994.334. Br J Cancer. 1994. PMID: 8080737 Free PMC article.

6

The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma.

van Moorselaar RJ, Ichikawa T, Schaafsma HE, Jap PH, Isaacs JT, van Stratum P, Ramaekers FC, Debruyne FM, Schalken JA. van Moorselaar RJ, et al. Among authors: debruyne fm. Urol Res. 1993;21(6):413-21. doi: 10.1007/BF00300078. Urol Res. 1993. PMID: 8171764

7

Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization.

Tamimi Y, van der Poel HG, Denyn MM, Umbas R, Karthaus HF, Debruyne FM, Schalken JA. Tamimi Y, et al. Among authors: debruyne fm. Cancer Res. 1993 Nov 15;53(22):5512-6. Cancer Res. 1993. PMID: 8221692

8

A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group.

Witjes JA, vd Meijden AP, Witjes WP, Doesburg W, Schaafsma HE, Debruyne FM. Witjes JA, et al. Among authors: debruyne fm. Eur J Cancer. 1993;29A(12):1672-6. doi: 10.1016/0959-8049(93)90102-l. Eur J Cancer. 1993. PMID: 8398292 Clinical Trial.

9

Prognostic value of karyometric and clinical characteristics in renal cell carcinoma. Quantitative assessment of tumor heterogeneity.

van der Poel HG, Mulders PF, Oosterhof GO, Schaafsma HE, Hendriks JC, Schalken JA, Debruyne FM. van der Poel HG, et al. Among authors: debruyne fm. Cancer. 1993 Nov 1;72(9):2667-74. doi: 10.1002/1097-0142(19931101)72:9<2667::aid-cncr2820720924>3.0.co;2-0. Cancer. 1993. PMID: 8402488

10

Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects.

Vet JA, Bringuier PP, Schaafsma HE, Witjes JA, Debruyne FM, Schalken JA. Vet JA, et al. Among authors: debruyne fm. Lab Invest. 1995 Dec;73(6):837-43. Lab Invest. 1995. PMID: 8558845

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

668 results

Search Page

Filters